Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Only a small percentage of people who inject drugs and those with sexual risk factors received the cancer-preventing vaccine.
Most people who received Rubraca maintenance therapy experienced tumor regression or had stable disease.
Black women, as well as those with Medicaid or no insurance, were less likely to receive surgery and more likely to die.
“The simplicity of this approach means that it is promising to take forward” to a human vaccine, researchers say.
“We wanted to understand how these precancerous cells may impact neighboring cancer,” says Christian Young, PhD.
Answer: It’s complicated …
The vaccine, based on an individual’s own tumor cells, improved survival time and proved safe in an early-stage trial.
Bintrafusp shrank tumors in over a third of patients with cervical, anal or head and neck cancer.
Identifying a tumor’s genetic mutations brings researchers closer to predicting treatment response.
Researchers continue to develop new drugs that target cancer with specific genetic mutations anywhere in the body.
Two types of immunotherapy plus chemotherapy shrank tumors in most patients in an early study.
Recognizing those who have made significant contributions to our understanding of the diagnosis, prevention and treatment of cancer
Failure to catch cancer early means many younger patients are diagnosed with advanced disease.
A high-fiber diet may help checkpoint medications work better—but probiotic supplements could interfere with response.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.